 n on the work of the remuneration 
committee in 202 4 is set out in the corporate governance report included in the Annual Report 202 4. 
Remuneration of the Board of Directors is not covered by this report. Such remuneration is resolved 
annually by the annual general meeting and disclosed in Note 14 to the Financial Statements of the 
Parent Company in the Annual Report 202 4. 
Key Developments 202 4 
Company performance in 202 4 
The CEO summarizes the Company’s overall performance in his statement in the Annual Report 202 4. 
In addition, the directors ’ report included in the Annual Report 202 4 summarizes the Company’s 202 4 
business and operations. The Company’s remuneration guidelines: scope, purpose, and deviations 
A prerequisite for the successful implementation of the Company’s business strategy and 
safeguarding of its long -term interests, including its sustainability, is that the Company is able to recruit 
and retain highly qualified personnel, consequently, it is nece 14 to the Consolidated Financial Statements in Hansa Biopharma’s Annual Report 
2024.Remuneration report 2024 continued 112
Hansa Biopharma Annual Report 2024Overview Strategy Growth Shareholder 
informationDirectors’ 
reportFinancials Governance Remuneration Glossary

6 Remuneration report 2024 continued Application of performance criteria related to the 202 4 CEO compensation 
Both, long -term and short -term performance measures have been selected to reflect key milestones in delivering the Company’s strategy and to encourage behaviour which is in the long -term interest of the 
Company. This is reflected in the performance criteria related to the Company’s long -term incentive programs as well as the corporate objectives applied to performance measurement related to the short -term 
incentive program of Hansa. In selecting performance measures, the strategic objectives as well as short -term and long -term business priorities have been considered. 
In 202 4, the share rights progra to 80% of the performance targets for all other 
members of the executive management. 
Table 4 – Criteria for payment of variable short -term compensation Name, Position Description of the criteria related to the corporate goals 2024 corporate goals Overall weight a) Measured goal achievement and b) Actual weighted outcome Søren Tulstrup, CEO Imlifidase commercial launch – Sales, market access, EMA post-approval commitments 2 sub-goals 20% a) 80% b) 17% Progressing pipeline activities in transplantation, autoimmune indications, gene therapy and HNSA-5487 6 sub-goals 45% a) 100% b) 45% Business development and financial strength 2 sub-goals 30% a) 50% b) 15% Corporate Social Responsibility 1 sub-goal 5% a) 100% b) 5% Total: 82% 
 
Comparative information on remuneration and Company performance 2024 2023 CEO remuneration Søren Tulstrup, CEO SEK 14,101k SEK 13,369k 
Company’s performance 
 Achievement of the annual corporate objectives 82% 85% 
 Operating profit / (loss) SEK ( 637,878k) S